Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation or decreased ventricular function. The broad implementation of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, the emergence of new devices, and the experience acquired by operators have brought this treatment to off-label indications such...
Paravalvular Leak (PVL) occurs in 5 to 17% of patients undergoing surgical valve replacement. Percutaneous device closure of PVL represents an alternative to repeat surgery. All centers in UK and Ireland performing percutaneous PVL closure delivered their data to the UK PVL registry. Data were analyzed for factors associated with mortality and major cardiovascular...
Original title: Initial German Experience With Tranapical Implantation of a Second-Generation Trascatheter heart Valve for the Treatment of Aortic Regurgitation. Reference: Moritz Seiffert, et al. JACC Cardiovasc Interv. 2014 Oct;7(10):1168-74. There is a group of patients with severe aortic regurgitation and they are not candidates for surgery; percutaneous implant is an option, but until now, there is little...
Original title: 5-Year Outcome After Aortic Valve Implantation Reference: Stefan Toggweiler, et al. J Am Coll Cardiol 2013;61:413–9 Percutaneous aortic valve implantation (TAVI) is now a valid strategy as we know its short and medium term evolution but we do not have enough information available about the long term. The aim of this study was to analyze the...